4 recruiting, 1 completed, 1 unknown. 6 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 4, Completed 1, Unknown 1 |
| Phase 2 | 6 | Recruiting 4, Completed 1, Unknown 1 |
Follow Advanced Solid Malignancies: new trials by email Literature Review of Advanced Solid Malignancies trials Research Report on Advanced Solid Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies BMS-986523, Gemcitabine, Nab-Paclitaxel - Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 252 | 2025-11-25 | 2026-05-28 |
| Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies GIM122 - Advanced Solid Malignancies | Phase 1 / Phase 2 | Recruiting | Georgiamune Inc | 111 | 2023-12-12 | 2026-08-17 |
| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391 - Advanced Solid Malignancies | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 695 | 2022-06-24 | 2026-10-05 |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors PRJ1-3024 - Advanced Solid Tumor, Advanced Solid Malignancies | Phase 1 / Phase 2 | Recruiting | Zhuhai Yufan Biotechnologies Co., Ltd | 267 | 2022-05-30 | 2024-12-17 |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies CFI-402411, Pembrolizumab - Advanced Solid Malignancies | Phase 1 / Phase 2 | Unknown | Treadwell Therapeutics, Inc | 170 | 2020-08-31 | 2025-05-21 |
| Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies CT7001, Fulvestrant - Advanced Solid Malignancies | Phase 1 / Phase 2 | Completed | Carrick Therapeutics Limited | 124 | 2017-11-14 | 2026-06-23 |
Pancreatic Neoplasms (2) · Astrocytoma (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lung Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1)
Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Pancreatic Diseases (2) · Adnexal Diseases (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Fallopian Tube Diseases (1)
pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Cetuximab (1) · Fulvestrant (1) · Gemcitabine (1) · Temozolomide (1) · trastuzumab deruxtecan (1)
AstraZeneca (1) · Bristol-Myers Squibb (1) · Carrick Therapeutics Limited (1) · Georgiamune Inc (1) · Treadwell Therapeutics, Inc (1) · Zhuhai Yufan Biotechnologies Co., Ltd (1)
United States (5) · Canada (2) · Spain (2) · United Kingdom (2) · Australia (1) · China (1) · Germany (1) · Hong Kong (1) · South Korea (1) · Sweden (1)
Matthew Krebs, MBChB PhD (1) · Omid Hamid, Dr (1) · Omid Hamid, MD (1)
PMID 32385714, PMID 37488191, PMID 37967136
2017 (1), 2023 (1), 2025 (1)